OpenOnco
UA EN
Plan Builder Onco Wiki Tumor Board

Onco Wiki / Biomarker

HIV status (4th-gen Ag/Ab combo screening)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDBIO-HIV-STATUS
TypeBiomarker
Aliases
Anti-HIVHIV serologyHIV statusHIV-1/2 Ag/AbСтатус ВІЛ (4-е покоління Ag/Ab скринінг)
Statusreviewed 2026-04-26 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025

Biomarker Facts

Biomarker typeviral_serology
Measurement
MethodFourth-generation HIV-1/2 antigen/antibody combo immunoassay (detects p24 antigen + anti-HIV-1/2 antibodies; window period ~10-14 days). Reactive screen → confirmatory HIV-1/2 antibody differentiation assay + HIV-1 RNA viral load if newly diagnosed.
Unitscategorical: HIV+ (with VL/CD4 if known) | HIV-
Related biomarkersBIO-HBV-STATUS BIO-HCV-STATUS BIO-EBV-STATUS

Notes

Mandatory pre-treatment screening for any aggressive lymphoma (Burkitt, DLBCL, plasmablastic, primary effusion) and Hodgkin lymphoma — HIV-associated subtypes have distinct biology, increased CNS-IPI risk, and require coordinated cART before / during cytotoxic therapy. HIV+ does NOT contraindicate standard regimens but requires: - cART continuation throughout cytotoxic therapy (avoid AZT — myelotoxic; integrase-inhibitor backbone preferred) - PJP + MAC prophylaxis if CD4 < 200 - CNS prophylaxis (intrathecal MTX) for HIV-associated DLBCL / Burkitt regardless of CNS-IPI score - Screen for KSHV / HHV-8 if effusion lymphoma suspected Wired into CHL, DLBCL, Burkitt, MM, SMZL 1L algorithm etiology rails (notes only at present — full branching on HIV+ deferred to next round). reviewer_signoffs: 0 # STUB — pending two Clinical Co-Lead approvals

Used By

Algorithms

Biomarker

Indications

Questionnaires